GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Autobio Diagnostics Co Ltd (SHSE:603658) » Definitions » EBIT

Autobio Diagnostics Co (SHSE:603658) EBIT : ¥1,480 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Autobio Diagnostics Co EBIT?

Autobio Diagnostics Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥368 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,480 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Autobio Diagnostics Co's annualized ROC % for the quarter that ended in Mar. 2024 was 15.03%. Autobio Diagnostics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 21.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Autobio Diagnostics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.18%.


Autobio Diagnostics Co EBIT Historical Data

The historical data trend for Autobio Diagnostics Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autobio Diagnostics Co EBIT Chart

Autobio Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 909.46 873.58 1,078.23 1,314.95 1,387.09

Autobio Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 275.51 343.95 404.40 363.22 368.16

Competitive Comparison of Autobio Diagnostics Co's EBIT

For the Medical Devices subindustry, Autobio Diagnostics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autobio Diagnostics Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Autobio Diagnostics Co's EV-to-EBIT falls into.



Autobio Diagnostics Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,480 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Autobio Diagnostics Co  (SHSE:603658) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Autobio Diagnostics Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1355.052 * ( 1 - 9.15% )/( (7749.194 + 8633.265)/ 2 )
=1231.064742/8191.2295
=15.03 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11554.058 - 1617.804 - ( 2187.06 - max(0, 2483.163 - 6613.021+2187.06))
=7749.194

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11605.923 - 1390.125 - ( 1582.533 - max(0, 2056.935 - 6618.533+1582.533))
=8633.265

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Autobio Diagnostics Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1472.64/( ( (3882.656 + max(2591.322, 0)) + (3905.937 + max(3420.422, 0)) )/ 2 )
=1472.64/( ( 6473.978 + 7326.359 )/ 2 )
=1472.64/6900.1685
=21.34 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1153.256 + 778.288 + 2444.42) - (1617.804 + 0 + 166.838)
=2591.322

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1106.91 + 833.391 + 3045.721) - (1390.125 + 0 + 175.475)
=3420.422

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Autobio Diagnostics Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=1479.739/28544.709
=5.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Autobio Diagnostics Co EBIT Related Terms

Thank you for viewing the detailed overview of Autobio Diagnostics Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Autobio Diagnostics Co (SHSE:603658) Business Description

Traded in Other Exchanges
N/A
Address
No.199, 15th Avenue, National Economic and Technological Development Area, Zhengzhou, CHN, 450016
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, marketing and service of clinical diagnostic products, including immunoassay, microbiology and biochemical products. It focuses on the common development of both reagents and instruments. Reagents products include immunoassay, biochemistry, microbiology, and IVD subdivision areas, and instruments include both full automation and semi-automation instruments and systems. Geographically it holds a strong distribution network with thousands of distributors in the Chinese market.
Executives
Miao Yong Jun Director

Autobio Diagnostics Co (SHSE:603658) Headlines

No Headlines